RxDoctor Payments Data

Mouhanna Abu Ghanimeh, MD

Gastroenterology · Sioux Falls, SDNPI 1962812982

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,682 of the $34,116 with a category attached, or 75.3%. Boston Scientific accounts for 87.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $25,185 and has fallen 83.5% since, to $4,151 in 2025. Among gastroenterology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,116in general payments, 2019–2025

Across 71 payments — averaging $480.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$30K
  • Olympus Corporation Of The Americas$2K
  • Ovesco Endoscopy USA, Inc.$1K
  • Cook Medical LLC$682
  • AbbVie$114
  • Apollo Endosurgery US Inc$111
  • plus $391 from 6 others

What the payments were for

  • Grants$25,68275%
  • Travel & lodging$6,28718%
  • Food & beverage$2,0676%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,116 in reported general payments places this provider in the 90th percentile of 41 gastroenterology providers in South Dakota.

See all gastroenterology providers in South Dakota

Medicare billing

Part B allowed, 2024
$78,729
Medicare patients
205
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$19,962
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg43$1,305
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg15$287
Omeprazole14$105
Ondansetron Hcl50$61
Ciprofloxacin Hcl23$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$114$19,96215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 gastroenterology providers in South Dakota.

Other gastroenterology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →